biotech

Strong clinical data, record deal activity and renewed investor confidence are driving the next phase of growth and outsized returns.

The year's biggest returns came from unexpected places, revealing how investor enthusiasm shifted well beyond Big Tech.

Disciplined pricing, capital constraints, active M&A and adaptive regulation is setting the stage for compelling investment opportunities.

Global Biotech is surging as policy fears fade and innovation takes centre stage. Here’s what’s driving the comeback into 2026.

Shortselling and the latest trial results

For this brand new episode of Finding the Front we are so fortunate to have biotech and life sciences veteran Matt Callahan on the show.

Selective stock-picking and conviction drove HB Biotech’s strong 2024 performance. Read our insights on navigating today’s biotech market.

Find out where the experts see big growth opportunities and the ways they are investing.

Extended interview with CEO Gary Phillips

This $60m ASX-listed biotech, with a cutting-edge pipeline of transformative therapies, stands at a key inflection point for value creation.